SynAging puts disease-inducing misfolded-protein-oligomers involved in the earliest stages of age-related neurodegenerative diseases in the center of the drug discovery processes.
A number of neurodegenerative diseases and some systemic diseases are caused by misfolded-protein-aggregates. In the literature (including SynAging’s publications), there is accumulating evidence for a critical role of oligomers of low molecular weight (soluble and diffusible assemblies) in synaptic and neuronal degeneration, and more generally in cell toxicity. This toxicity is already occurring in the early stages of amyloid-associated diseases, but sometime only observed at a later advanced stage.
SynAging has mastered the reproducible preparation and use of such oligomerized and polymerized protein preparations and the evaluation of their toxic effects in vitro, in vivo and in ex vivo biochemical studies of marker proteins.
- The main advantage of SynAging’s technology is the reproducible preparation of low number oligomers at high concentrations from various amyloidogenic proteins or peptides inducing consistent effects in vitro and in vivo.
- The use of the same oligomer preparation enables a fast and reliable transition from in vitro to in vivo model, increasing translatability and consistency of results.
- SynAging’s technology allows the easy combination of protein oligomer induced stress plus age dependent stress that is one of the major virtues* for a valid animal model and consequently the discovery of efficient therapeutics for neurodegenerative diseases.
* Review of Ramanan & Sykin “Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.”, http://www.ncbi.nlm.nih.gov/pubmed/24093081